What does Pharmatel-Immo do?

Pharmatel-Immo is filed with the CBE under the catch-all “Overige zakelijke dienstverlening”, a code that says little about what the company actually does. Private Limited, started on 13 July 2015, 1 establishment.

What is the address of Pharmatel-Immo?

The registered office of Pharmatel-Immo is located at Kleimoer 4, 9030 Gent.

Is Pharmatel-Immo still active?

Yes. According to the CBE (29 October 2026) Pharmatel-Immo is active, legal situation “Normale toestand”, started on 13 July 2015.

Is Pharmatel-Immo registered on Peppol?

Yes, Pharmatel-Immo is registered on the Peppol network with ID 0208:0634631111.

What is the enterprise number of Pharmatel-Immo?

The enterprise number of Pharmatel-Immo is BE0634631111.

When was Pharmatel-Immo founded?

Pharmatel-Immo was founded on 13 July 2015.

Who are the directors of Pharmatel-Immo?

According to the 2025 annual accounts, the directors of Pharmatel-Immo are: Ariane De Ganck, ARDENA HOLDING NV, Arnout Everaert.

Is Pharmatel-Immo a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 13 July 2015; 5 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account.

How much profit did Pharmatel-Immo make in 2025?

Pharmatel-Immo posted a profit after taxes of € 82,078 in financial year 2025.

What is the revenue of Pharmatel-Immo?

As a small company, Pharmatel-Immo is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 495,799.

How much does an employee at Pharmatel-Immo earn?

The average wage cost per full-time employee at Pharmatel-Immo was € 49,900 in 2025: staff costs of € 49,892 for 1 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does Pharmatel-Immo have?

According to the 2025 annual accounts, Pharmatel-Immo has 1 full-time equivalents (FTE).

Pharmatel-Immo (Private Limited) - Gent - BE0634631111

Dossier Pharmatel-Immo, printed on 29 October 2026 from databakkes.be/en/0634631111/pharmatel-immo. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 28 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

Pharmatel-Immo from Gent, company number BE0634631111, closed financial year 2025 with a result of € 82,078 after tax. For that financial year Pharmatel-Immo recorded a gross margin of € 495,799 and equity of € 164,248. Compared with financial year 2024, the result moved from € 136,849 to € 82,078. The company is profitable. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.

What it is worth Growing

€ 164,248

▲ 100% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 82,078

▼ 40% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 3,464

▼ 91% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 145,648.

People and assets in 2025

Full-time equivalents

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 49,892

▼ 18% vs 2024

€ 49,900 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 54,589

▼ 18% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 7 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 2 million

▲ 44% vs 2024

€ 287,159 is repaid this year. At this pace the long-term loan is gone in ≈ 7 years.

Owed to suppliers

€ 69,649

▲ 255% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 178,785

▲ 76% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 531,708 Gross margin 2022: € 531,708 First fiscal year in the series	€ 545,563 Gross margin 2023: € 545,563 ▲ 3% vs 2022 (€ 531,708) Favourable step	€ 600,390 Gross margin 2024: € 600,390 ▲ 10% vs 2023 (€ 545,563) Favourable step	€ 495,799 Gross margin 2025: € 495,799 ▼ 17% vs 2024 (€ 600,390) Unfavourable step	▼ 17%
Profit after taxes	€ 125,176 Profit after taxes 2022: € 125,176 First fiscal year in the series	€ 113,862 Profit after taxes 2023: € 113,862 ▼ 9% vs 2022 (€ 125,176) Unfavourable step	€ 136,849 Profit after taxes 2024: € 136,849 ▲ 20% vs 2023 (€ 113,862) Favourable step	€ 82,078 Profit after taxes 2025: € 82,078 ▼ 40% vs 2024 (€ 136,849) Unfavourable step	▼ 40%
Equity	€ 647,511 Equity 2022: € 647,511 First fiscal year in the series	€ 761,373 Equity 2023: € 761,373 ▲ 18% vs 2022 (€ 647,511) Favourable step	€ 82,170 Equity 2024: € 82,170 ▼ 89% vs 2023 (€ 761,373) Unfavourable step	€ 164,248 Equity 2025: € 164,248 ▲ 100% vs 2024 (€ 82,170) Favourable step	▲ 100%
Total debts	€ 2,781,730 Total debts 2022: € 2,781,730 First fiscal year in the series	€ 2,350,064 Total debts 2023: € 2,350,064 ▼ 16% vs 2022 (€ 2,781,730) Favourable step	€ 2,545,901 Total debts 2024: € 2,545,901 ▲ 8% vs 2023 (€ 2,350,064) Unfavourable step	€ 2,352,456 Total debts 2025: € 2,352,456 ▼ 8% vs 2024 (€ 2,545,901) Favourable step	▼ 8%
Cash	€ 91,152 Cash 2022: € 91,152 First fiscal year in the series	€ 9,501 Cash 2023: € 9,501 ▼ 90% vs 2022 (€ 91,152) Unfavourable step	€ 40,010 Cash 2024: € 40,010 ▲ € 30,508 vs 2023 (€ 9,501) Favourable step	€ 3,464 Cash 2025: € 3,464 ▼ 91% vs 2024 (€ 40,010) Unfavourable step	▼ 91%
Land & buildings	€ 3,041,854 Land & buildings 2022: € 3,041,854 First fiscal year in the series	€ 2,876,477 Land & buildings 2023: € 2,876,477 ▼ 5% vs 2022 (€ 3,041,854) Unchanged	€ 2,382,018 Land & buildings 2024: € 2,382,018 ▼ 17% vs 2023 (€ 2,876,477) Unchanged	€ 2,234,752 Land & buildings 2025: € 2,234,752 ▼ 6% vs 2024 (€ 2,382,018) Unchanged	▼ 6%
Retained profit	€ 227,459 Retained profit 2022: € 227,459 First fiscal year in the series	€ 341,321 Retained profit 2023: € 341,321 ▲ 50% vs 2022 (€ 227,459) Favourable step	€ 63,570 Retained profit 2024: € 63,570 ▼ 81% vs 2023 (€ 341,321) Unfavourable step	€ 145,648 Retained profit 2025: € 145,648 ▲ 129% vs 2024 (€ 63,570) Favourable step	▲ 129%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 414,600 Dividend 2024: € 414,600 Unchanged (€ 0) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 414,600) Unchanged	▼ 100%
Bank debt	€ 1,796,444 Bank debt 2022: € 1,796,444 First fiscal year in the series	€ 1,578,155 Bank debt 2023: € 1,578,155 ▼ 12% vs 2022 (€ 1,796,444) Favourable step	€ 1,392,436 Bank debt 2024: € 1,392,436 ▼ 12% vs 2023 (€ 1,578,155) Favourable step	€ 2,001,788 Bank debt 2025: € 2,001,788 ▲ 44% vs 2024 (€ 1,392,436) Unfavourable step	▲ 44%
Balance sheet total	€ 3,429,241 Balance sheet total 2022: € 3,429,241 First fiscal year in the series	€ 3,111,437 Balance sheet total 2023: € 3,111,437 ▼ 9% vs 2022 (€ 3,429,241) Unchanged	€ 2,628,071 Balance sheet total 2024: € 2,628,071 ▼ 16% vs 2023 (€ 3,111,437) Unchanged	€ 2,516,704 Balance sheet total 2025: € 2,516,704 ▼ 4% vs 2024 (€ 2,628,071) Unchanged	▼ 4%
Employees (FTE)	1 Employees (FTE) 2022: 1 First fiscal year in the series	1 Employees (FTE) 2023: 1 Unchanged (1) Unchanged	1 Employees (FTE) 2024: 1 Unchanged (1) Unchanged	1 Employees (FTE) 2025: 1 Unchanged (1) Unchanged

Key figures of Pharmatel-Immo, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Pharmatel-Immo?

What happened at Pharmatel-Immo in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 31, 2026 New annual accounts for financial year 2025: profit of € 82,078 (▼ 40% vs 2024). filed late Source: NBB ↗
2026 Ariane De Ganck became a director. NBB
2026 ARDENA HOLDING NV became a director. NBB
2026 Arnout Everaert became a director. NBB
Jul 13, 2015 New establishment in Gent. KBO
Jul 13, 2015 Start of the company according to the CBE. KBO

In short

From € 125,176 profit in 2022 to € 82,078 profit in 2025.

Paid € 231,150 in corporate taxes since 2022.

Best year ever: 2024, with € 136,849 profit.

On average € 495,800 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

PHARMATEL 100%

The stake of PHARMATEL comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Pharmatel-Immo

Behind Pharmatel-Immo are Ariane De Ganck, ARDENA HOLDING NV and Arnout Everaert. The shares are held by PHARMATEL (100%).

Directors

According to the 2025 annual accounts

Ariane De Ganck

Director

Also active at: Ardena Gent

since 2026

ARDENA HOLDING NV

Director · represented by Jeremie Trochu

Also active at: Ardena Gent

since 2026

Arnout Everaert

Director

Also active at: Ardena Gent

since 2026

Shareholders

PHARMATEL

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Kleimoer 4

9030 Gent

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

Ardena Gent same network

€ 26.7 million revenue · 2025

Ardena Holding same network

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0634.631.111
VAT number: BE 0634.631.111
Registered office: Kleimoer 4, 9030 Gent
Names & denominations: Pharmatel-Immo
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 13 July 2015
Peppol: Active · Active since 7 May 2026
Activities · NACE: Overige zakelijke dienstverlening, neg

View on CBE Public ↗ Annual accounts (NBB) ↗

Pharmatel-Immo

Warning lights

Financials

What happened to Pharmatel-Immo?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions